Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study to Evaluate [18F]ACI-19626 as a Potential PET Radioligand for Imaging TDP-43 Inclusions in the Brain of Patients With Suspected TDP-43 Proteinopathies Compared With Healthy Controls

NCT06891716 is registered in ClinicalTrials.gov with AC Immune SA as lead sponsor.

NCT NCT06891716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06891716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study to Evaluate [18F]ACI-19626 as a Potential PET Radioligand for Imaging TDP-43 Inclusions in the Brain of Patients With Suspected TDP-43 Proteinopathies Compared With Healthy Controls
Lead sponsor
AC Immune SA
Phase
Phase 1
Overall status
Recruiting
Start date
January 21, 2025
Completion date
November 30, 2026
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease (ad), amyotrophic lateral sclerosis (als), frontotemporal dementia (ftd), suspected limbic predominant age-related tdp-43 encephalopathy (late), tdp-43 proteinopathies